ORTEXORTEX News
Tracking MCRI? Get live short interest, options flow, and signals on ORTEX.Sign up free →
MC
Earnings PreviewMCRI

Truist Raises Target as MCRI Heads Into Q2 Print

By ORTEX News · Edited by , Editor, ORTEX News2 min readdata as of 21 Jul 2026, 03:55

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Monarch Casino & Resort reports second-quarter results on July 22, with analysts raising targets into the release but the broader peer group under pressure — a contrast the earnings print will need to resolve.

The most notable pre-earnings move came from Truist Securities yesterday, lifting its price target from $125 to $144 while keeping a Buy rating. That target sits well above the current consensus mean of $121, and meaningfully above the $124.38 close. Wells Fargo followed earlier in the week, raising its Equal-Weight target to $116 from $99 — a chunky revision that still implies modest downside from current levels. The direction of travel from the Street is clearly higher, but the ratings split tells a more cautious story: Truist is the lone Buy among the recent movers, with Wells Fargo and Macquarie both sitting on the sidelines at Equal-Weight and Neutral respectively. Bulls point to the 19% year-over-year EBITDA growth and 9% revenue expansion reported in Q1, along with MCRI's demonstrated ability to take market share in both Reno and Black Hawk. Bears flag macroeconomic uncertainty and tougher sequential comparisons in Q2, with fuel-sensitive drive-in and fly-in traffic a specific risk to gaming volumes.

Options positioning leans bullish rather than defensive heading into the number. The put/call ratio is running at 0.0625, essentially in line with its 20-day average of 0.069 and close to the 52-week low of 0.047 — a signal that options traders have not meaningfully hedged for downside. The stock is down 5% over the past month to $124.38, though it has stabilized near flat on the week, suggesting sellers have been absorbed. Short interest, meanwhile, tells a less alarming story than the headline trend implies: at 2.75% of the free float it remains low in absolute terms, despite a sharp jump in borrowed shares over the past month. Borrow availability is extremely loose — far more shares sit available to lend than are currently borrowed — and cost to borrow is negligible at 0.56%. There is no short squeeze dynamic in the lending market.

The ownership picture adds one wrinkle worth noting. Insider selling has been a consistent theme: CEO John Farahi sold more than 114,000 shares in late April at $118, a transaction worth over $13.5 million, with further smaller sales in May. Net insider activity over the past 90 days has been a disposal of around 240,000 shares, totaling roughly $28 million in value. That scale of selling by the founder and chairman is notable against a stock trading near multi-month highs, though it may reflect personal liquidity management rather than a view on near-term prospects. Correlated US gaming peers PENN and RRR both dipped on the week, underperforming MCRI's flat finish, which itself is a modest positive for relative sentiment heading in.

Tomorrow's print is less a test of whether Monarch is growing — Q1 results confirmed that — and more a test of whether Q2 margins held up against the tougher comparisons and macro headwinds the company flagged, and whether management's outlook is strong enough to justify a stock that has now moved well above where most of its covering analysts had set their targets just three months ago.

Stocks in this article

See the live data behind this article on ORTEX.

Open MCRI on ORTEX →

How this article was generated

Generated
21 Jul 2026, 04:13
Data as of
21 Jul 2026, 03:55
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.